S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00

QIAGEN Stock Forecast, Price & News

-1.50 (-2.73 %)
(As of 10/27/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
668,273 shs
Average Volume
763,685 shs
Market Capitalization
$12.18 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QIAGEN and its competitors with MarketBeat's FREE daily newsletter.



QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Year Founded

Sales & Book Value

Annual Sales
$1.87 billion
Cash Flow
$3.17 per share
Book Value
$12.27 per share


Net Income
$359.19 million
Pretax Margin




Free Float
Market Cap
$12.18 billion
Next Earnings Date
11/3/2021 (Confirmed)
Fiscal Year End


Overall MarketRank

1.38 out of 5 stars

Medical Sector

1102nd out of 1,372 stocks

Biological Products, Except Diagnostic Industry

168th out of 197 stocks

Analyst Opinion: 1.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

QIAGEN (NYSE:QGEN) Frequently Asked Questions

Is QIAGEN a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QIAGEN in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" QIAGEN stock.
View analyst ratings for QIAGEN
or view top-rated stocks.

What stocks does MarketBeat like better than QIAGEN?

Wall Street analysts have given QIAGEN a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but QIAGEN wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is QIAGEN's next earnings date?

QIAGEN is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for QIAGEN

How can I listen to QIAGEN's earnings call?

QIAGEN will be holding an earnings conference call on Thursday, November 4th at 9:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were QIAGEN's earnings last quarter?

QIAGEN (NYSE:QGEN) issued its quarterly earnings results on Thursday, July, 29th. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.01. The firm had revenue of $567.31 million for the quarter, compared to analyst estimates of $562.35 million. QIAGEN had a net margin of 21.92% and a trailing twelve-month return on equity of 21.31%. During the same quarter in the previous year, the business earned $0.55 earnings per share.
View QIAGEN's earnings history

How has QIAGEN's stock been impacted by Coronavirus (COVID-19)?

QIAGEN's stock was trading at $41.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, QGEN shares have increased by 30.0% and is now trading at $53.44.
View which stocks have been most impacted by COVID-19

What guidance has QIAGEN issued on next quarter's earnings?

QIAGEN updated its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided EPS guidance of $2.420-$ for the period, compared to the Thomson Reuters consensus estimate of $2.470. The company issued revenue guidance of $2.09 B-, compared to the consensus revenue estimate of $2.27 billion.

What price target have analysts set for QGEN?

12 equities research analysts have issued 12-month target prices for QIAGEN's shares. Their forecasts range from $49.53 to $58.00. On average, they expect QIAGEN's share price to reach $52.27 in the next twelve months. This suggests that the stock has a possible downside of 2.2%.
View analysts' price targets for QIAGEN
or view top-rated stocks among Wall Street analysts.

Who are QIAGEN's key executives?

QIAGEN's management team includes the following people:
  • Thierry Bernard, Chief Executive Officer & Managing Director
  • Barthold Piening, Senior Vice President & Head-Global Operations
  • Roland Sackers, Chief Financial Officer & Managing Director
  • Stephany Foster, Senior Vice President & Head-Human Resources
  • John Gilardi, Vice President & Head-Investor Relations

What is Thierry Bernard's approval rating as QIAGEN's CEO?

33 employees have rated QIAGEN CEO Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among QIAGEN's employees.

What other stocks do shareholders of QIAGEN own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QIAGEN investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is QIAGEN's stock symbol?

QIAGEN trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are QIAGEN's major shareholders?

QIAGEN's stock is owned by many different retail and institutional investors. Top institutional investors include DekaBank Deutsche Girozentrale (0.87%), Frontier Capital Management Co. LLC (0.06%), Nisa Investment Advisors LLC (0.01%), Bellecapital International Ltd. (0.01%), West Family Investments Inc. (0.00%) and Veriti Management LLC (0.00%).

Which institutional investors are selling QIAGEN stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, and Nisa Investment Advisors LLC.

Which institutional investors are buying QIAGEN stock?

QGEN stock was purchased by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Bellecapital International Ltd., Veriti Management LLC, and West Family Investments Inc..

How do I buy shares of QIAGEN?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is QIAGEN's stock price today?

One share of QGEN stock can currently be purchased for approximately $53.44.

How much money does QIAGEN make?

QIAGEN has a market capitalization of $12.18 billion and generates $1.87 billion in revenue each year. The company earns $359.19 million in net income (profit) each year or $2.15 on an earnings per share basis.

How many employees does QIAGEN have?

QIAGEN employs 5,610 workers across the globe.

What is QIAGEN's official website?

The official website for QIAGEN is www.qiagen.com.

Where are QIAGEN's headquarters?

QIAGEN is headquartered at HULSTERWEG 82, VENLO P7, 5912.

How can I contact QIAGEN?

QIAGEN's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at (177) 355-6600 or via email at [email protected].

This page was last updated on 10/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.